We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Near-Infrared Set-Up Evaluated for Dried Blood Spot Hematocrit

By LabMedica International staff writers
Posted on 11 Nov 2021
Print article
Image: The NIRFlex N-500 Fourier Transformation spectrometer (Photo courtesy of Büchi Labortechnik)
Image: The NIRFlex N-500 Fourier Transformation spectrometer (Photo courtesy of Büchi Labortechnik)
Capillary dried blood sampling, where samples are obtained from a finger or heel prick, has many advantages over traditional blood sampling. The best-known dried blood sampling technique is the generation of dried blood spots (DBS) on filter paper.

Conventional DBS cards remain valuable to collect dried blood microsamples, not in the least because DBS sampling is well known in the newborn and pediatrics field, the analysis can easily be automated and the cost is low. Amongst the approaches that were developed to cope with this issue, is the hematocrit (Hct) prediction of DBS using near-infrared (NIR) spectroscopy.

Clinical Scientists at the Ghent University Hospital (Ghent, Belgium) and their colleagues collected blood from 12 healthy volunteers via finger prick and each volunteer provided three capillary DBS and three corresponding liquid capillary samples, the latter being collected via heparinized microcapillaries. Left-over venous EDTA-anti-coagulated patient samples were used to generate DBS by pipetting 25 µL of whole blood onto Whatman 903 filter paper.

The team determined Hct L/L (liter of cells/liter of blood) values with a Sysmex XN-5000 hematology analyzer (Sysmex, Kobe, Japan). The Hct of liquid capillary blood samples was determined via centrifugation in a Hct-centrifuge (5 minutes, 12,000 rpm), and then measured using a micro-hematocrit reader (Hawksley, Lancing, UK). NIR measurements were performed on a NIRFlex N-500 Fourier Transformation spectrometer equipped with a fiber optics solids cell N500-007 (Büchi Labortechnik, Flawil, Switzerland). The results obtained via NIR for the DBS validation set (n = 49; singlicate analysis), measured at Day 0 and Day 5, were compared to those obtained with the hematology analyzer, being the standard method.

Using left-over EDTA-anticoagulated patient samples, the accuracy and precision, stability, and robustness were assessed. Furthermore, applicability of the method on capillary DBS was evaluated via finger prick samples. The investigators reported that the method validation amply met the pre-set acceptance criteria, with a maximum total precision of 4.5% and bias of 0.012 L/L. Also storage did not relevantly affect the Hct prediction, except for storage at 60 °C. The analysis of samples with a high hemolytic/icteric/lipemic index (HIL)-index showed that only lipemia had a significant effect on the Hct predictions. The mean difference was 0.035 L/L, which was considered acceptable.

The authors concluded that a commercially available NIR set-up was extensively and successfully validated, allowing non-contact Hct prediction of DBS with excellent accuracy and precision. This allows to correct for the Hct-based bias observed in partial-punch DBS analysis and the set-up of blood-plasma conversion factors, increasing the application potential of patient-centric sampling. The study was published on October 5, 2021 in the journal Clinica Chimica Acta.

Related Links:
Ghent University Hospital
Sysmex
Hawksley
Büchi Labortechnik


New
Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8
New
Silver Supplier
Receptor Destroying Enzyme
RDE II (Receptor Destroying Enzyme)
New
Automated R-AST Solution
Radian BC
New
Molecular Diagnostic System
FlashDetect Flash48

Print article

Channels

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.